BRAIN Biotech AG Appoints New Executive Vice President to Lead Enzyme Products Division
BRAIN Biotech AG has appointed Johan Jansen-Storbacka as Executive Vice President of its enzyme products business, signaling a strategic move to strengthen its position in the growing biocatalysts market and enhance integration between research and production capabilities.
BRAIN Biotech AG has appointed Johan Jansen-Storbacka as Executive Vice President of the BRAINBiocatalysts' enzyme products business, effective September 1, 2025. This appointment comes at a critical time for the biotechnology company as it seeks to expand its market presence and optimize operations across its global production network.
Jansen-Storbacka brings over 20 years of experience in biotechnology to the role, with extensive expertise in enzyme applications spanning industrial processes, animal nutrition, and home care sectors. He holds both an M.Sc. in Engineering and Management and an MBA, providing him with the technical and business acumen needed to lead the division. He succeeds Rod Sears-Black, who retired earlier this year, and takes over from interim leader Adriaan Moelker, CEO of BRAIN Biotech, who will now focus entirely on leading the overall group.
In his new position, Jansen-Storbacka will oversee approximately 140 employees and manage fermentation facilities in the UK along with production sites in continental Europe and the United States. His responsibilities include driving the company's strategy to strengthen its enzyme and fermentation business while ensuring closer integration of research and production activities throughout the organization. This integration is particularly important as BRAIN Biotech aims to enhance efficiency and scalability in producing specialty enzymes for food and life sciences industries.
Adriaan Moelker, CEO of BRAIN Biotech, emphasized the significance of this appointment, stating that Jansen-Storbacka's broad industry background and international experience make him well-suited to lead the enzyme products business. The company, which generated revenue of €54.6 million in the 2023/24 fiscal year with around 300 employees, is positioned to benefit from his leadership in navigating diverse end markets and advancing sustainable biological solutions. For more information about the company's operations, visit https://www.brain-biotech-group.com.
The appointment reflects BRAIN Biotech's commitment to expanding its biocatalysts division, which focuses on developing, producing, and distributing specialty enzymes, microorganisms, and ingredients. As industries increasingly seek sustainable alternatives and efficient processes, the demand for enzyme-based solutions is growing. Jansen-Storbacka's role will be pivotal in capitalizing on these trends, ensuring that BRAIN Biotech remains competitive in the global market. The company's additional production and research capabilities, including those through subsidiaries like Biocatalysts Ltd, can be explored at https://www.biocatalysts.com.
This leadership change underscores the strategic importance of the enzyme products business within BRAIN Biotech's portfolio. By appointing an experienced executive with a strong track record, the company aims to accelerate growth, improve operational synergy, and reinforce its position as a leader in biologization technologies. The move is expected to have positive implications for the company's innovation pipeline and market expansion efforts in the coming years.